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Patients with low-immunogenic tumors respond poorly to immune checkpoint blockade (ICB) targeting the pro-
grammed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway. Conversely, patients responding to ICB 
can experience various side effects. We have thus engineered a therapeutic scaffold that, when formed in situ, 
allows the local release of gemcitabine (GEM) and an anti–PD-L1 blocking antibody (aPDL1) with distinct release 
kinetics. The scaffold consists of reactive oxygen species (ROS)–degradable hydrogel that releases therapeutics in 
a programmed manner within the tumor microenvironment (TME), which contains abundant ROS. We found that 
the aPDL1-GEM scaffold elicits an immunogenic tumor phenotype and promotes an immune-mediated tumor 
regression in the tumor-bearing mice, with prevention of tumor recurrence after primary resection.
INTRODUCTION
Immune checkpoint blockade (ICB) targeting the programmed 
death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway (1, 2) 
induces remarkable clinical responses in various malignancies (3, 4), 
including melanoma, non–small cell lung, kidney, head and neck, 
and bladder cancers (5–7). However, only patients with immunogenic 
tumors characterized by high neoantigen burden (8), preinfiltration 
of effector T cells (9), and expression of PD-L1 (10, 11) seem to 
achieve durable clinical responses after the administration of ICB 
(12, 13). Moreover, clinical application of ICB has also been associated 
with various side effects in normal organs (14–16). On the basis of 
these studies, strategies aimed at promoting an immunogenic tumor 
phenotype, increasing ICB response, and avoiding severe side effects 
remain a central theme in the field of cancer immunotherapy (17).
Previous reports showed that prior chemotherapy enhanced the 
therapeutic outcome of immunotherapy (18–22), which also reversed 
chemoresistance after prolonged chemotherapy (20, 23). Although 
some chemotherapeutic drugs have modest activity when used as 
single treatments, their combination with immunotherapy may re-
sult in enhanced anticancer effects and can be used to promote an 
immunogenic tumor phenotype (24–26). In addition, engineered 
delivery vehicles and scaffolds are increasingly considered as promising 
tools for transporting immunotherapeutics (27–33), with decreased 
systemic toxicities. In addition, the regulated release of payloads and 
the kinetics of the degradation of the supporting matrix upon in vivo 
administration are aspects particularly relevant for the treatment 
efficacy (27, 33).
Here, we have generated an in situ formed bioresponsive scaffold 
suitable for localized chemoimmunotherapy, in which gemcitabine 
(GEM) and scaffold enhance an immunogenic tumor phenotype and 
ICB promotes subsequent therapeutic immune response (Fig. 1A). 
We hypothesized that injectable reactive oxygen species (ROS)– 
responsive hydrogel could be used to load and release therapeutics 
upon implantation into the tumor site because of highly abundant 
ROS, which are expressed within the tumor microenvironment (TME) 
and promote cancer development as well as progression (34–37). 
Here, we show that a clinically relevant prototype of ROS-degradable 
hydrogel scaffold promotes an immunogenic tumor phenotype via 
local GEM delivery and enhances antitumor responses through lo-
cal release of anti–PD-L1 blocking antibody (aPDL1) in the B16F10 
melanoma and 4T1 breast tumor [relatively low-immunogenic (38)] 
mouse models. Therapeutic advantage of this chemoimmunotherapy 
is also demonstrated by the prevention of tumor recurrence after pri-
mary resection.
RESULTS
Synthesis and characterization of in situ formed 
bioresponsive scaffold
ROS-responsive hydrogel was obtained by crosslinking poly(vinyl 
alcohol) (PVA) with a ROS-labile linker: N1-(4-boronobenzyl)-N3-(4- 
boronophenyl)-N1,N1,N3,N3-tetramethylpropane-1,3-diaminium 
(TSPBA) (fig. S1), which was synthesized via quaternization reac-
tion of N1,N1,N3,N3-tetramethylpropane-1,3-diamine with an excess 
of 4-(bromomethyl)phenylboronic acid (fig. S2). TSPBA contains 
two phenylboronic acids that complex with diols on PVA (39, 40). 
Formation of PVA-TSPBA hydrogel was further confirmed by a 
rheology test (fig. S3). Addition of TSPBA to PVA solution rapidly 
increased the elastic modulus (G′), demonstrating the formation of 
a network between the PVA chains (fig. S3, A to D). The hydrogel 
can be quickly formed after mixing the PVA and linkers (Fig. 1A 
and fig. S3, E and F). In vivo gel formation and degradation were 
then examined in healthy mice. The integrity of the gels remained 
up to 7 days, whereas the overall size of gels decreased gradually. At 
week 3 after injection, most gels were degraded at the injection sites 
(fig. S4), indicating their biodegradability.
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GEM and aPDL1 at therapeutically relevant doses (GEM, 5 mg/kg; 
aPDL1, 50 g) were encapsulated into the PVA-TSPBA hydrogel 
(200 l; 10%, w/w). The drug-loaded hydrogels showed similar rhe-
ology properties compared with the empty ones (fig. S3, D and F), 
indicating that the formation of the hydrogel was not significantly 
affected by the drug encapsulation. The morphology of the dried 
scaffold network was observed by cryo–scanning electron micros-
copy (Cryo-SEM), with a porous structure (Fig. 1B). To visualize 
the distribution of therapeutics in the hydrogels, fluorescein as a 
fluorescent surrogate for GEM (41) and Cy5.5-labeled aPDL1 were 
loaded into the hydrogel. In a confocal image of a frozen section of 
hydrogel, fluorescein displayed a uniform distribution, whereas the 
dotted signals associated with aPDL1 were detected inside the hy-
drogel (Fig. 1C).
The TSPBA can be oxidized and hydrolyzed when exposed to 
H2O2 in the TME, leading to the dissociation of the polymeric scaf-
fold (fig. S5) and the release of payloads. To verify the ROS-sensitive 
degradability of the hydrogels, samples were immersed in phosphate- 
buffered saline (PBS) containing 1.0 mM H2O2 at 37°C. Changes in 
the morphology of the scaffolds were observed over time (Fig. 1D). 
The release profiles of GEM and aPDL1 were quantified using high- 
performance liquid chromatography (HPLC) and enzyme-linked 
immunosorbent assay (ELISA), respectively. As expected, GEM and 
aPDL1 were released from the hydrogel in H2O2 solution with an 
increased rate compared to that in PBS only. Most of the GEM was 
released within 1 day, whereas aPDL1 showed a more sustained re-
lease profile, with 80% released within 3 days (Fig. 1, E and F). The 
release pattern was further examined in vivo after the peritumoral 
injection of the scaffold with payloads in the B16F10 mouse model. 
Confocal imaging of tumor sections (fig. S6) showed that the fluo-
rescein signal (fluorescent surrogate for GEM) was rapidly evident 
(within day 1), whereas the signal corresponding to aPDL1 increased 
gradually within 3 days. These distinct release dynamics facilitated 
the delivery of GEM and aPDL1 into the TME for the intended 
sequential effects.
Therapeutic scaffold for eliciting immunogenic  
tumor phenotype
Next, we measured the response of immune cells and tumor cells 
after treatment of scaffold loaded with GEM (GEM@Gel) in vivo. 
GEM was loaded into the hydrogel and injected peritumorally. We 
found that a high dose of GEM (25 mg/kg) within the GEM@Gel 
significantly (P = 0.0151) depleted the tumor-infiltrating lymphocytes 
(TILs) (fig. S7A) and had no significant effects on the survival (fig. 
S7, B and C). In contrast, empty hydrogel or a low dose of GEM 
(5 mg/kg) within the GEM@Gel increased the frequency of TILs at 
the tumor site (Fig. 2, A and B). To further assess the overall immune 
effects of the GEM@Gel within the TME, we examined the intratu-
moral presence of ROS, regulatory T cells (Tregs), myeloid-derived 
suppressor cells (MDSCs), and tumor-associated macrophages (TAMs). 
Intratumoral ROS were significantly (P < 0.001) reduced after the 
empty hydrogel or GEM@Gel implantation (fig. S8). Furthermore, 
Fig. 1. Schematic and characterization 
of in situ formed ROS-responsive 
gel scaffold. (A) Schematic of com-
bination chemoimmunotherapy using 
a ROS-degradable hydrogel scaffold 
to deliver GEM and aPDL1 into the TME. 
(B) Representative Cryo-SEM image 
of gel scaffold loaded with GEM and 
aPDL1. Scale bar, 0.5 m. Inset: Zoomed- 
in image of the scaffold. Scale bar,
0.1 m. (C) Representative fluorescent
images of a cryosection of hydrogel 
in which fluorescein isothiocyanate 
(FITC) (green) was used as a fluores-
cent surrogate for GEM and aPDL1 was 
labeled with Cy5.5 (red). Scale bar, 
25 m. (D) Morphology changes of
hydrogels in 1× PBS with and without 
H2O2 (1 mM) over 7 days. (E and F) Cu-
mulative release profiles of GEM (E)
and aPDL1 (F) from hydrogels in-
cubated with PBS with or without
H2O2 (1 mM). Data are means ± SEM. 
IgG, immunoglobulin G.
although Tregs were not significantly affected (fig. S9), we observed 
a significant (P < 0.001) reduction of MDSCs (CD45+CD11b+Gr-1+) 
and M2-polarized TAMs (CD206hiCD11b+F4/80+) (Fig. 2, C and D) 
(42). A significant (P < 0.001) reduction of TAMs was also observed 
in mice treated with empty hydrogel (Fig. 2D). Together, these data 
indicate that GEM@Gel enhances the frequency of TILs and reduces 
immunosuppressive cellular components.
Treatment of B16F10 cancer cells in vitro with GEM resulted in 
cell death and increased expression of PD-L1 in surviving cells. PD-L1 
expression on B16F10 cancer cells was found to be GEM dose- and 
time-dependent as assessed by flow cytometry, immunofluorescence, 
and Western blot (fig. S10, A and B). In vivo, GEM@Gel also induced 
PD-L1 expression on cancer cells, dendritic cells, and macrophages 
compared to the untreated tumors and tumors treated with empty 
hydrogels, as well as PD-1 expression in both CD4+ and CD8+ TILs 
(Fig. 2, E and F). PD-L1 expression in the tumor cells was increased 
in a time-dependent manner (fig. S11). Circulating type 1 T helper 
(TH1) cytokines were also measured before and after GEM@Gel 
Fig. 2. GEM@Gel implantation for eliciting immunogenic tumor phenotypes. B16F10 tumors harvested from mice implanted with hydrogels or GEM@Gel were ana-
lyzed by flow cytometry 2 days after treatment. (A) Representative flow cytometric analysis of T cell infiltration within the tumor and (B) corresponding quantification 
results. UnTx, untreated. (C) Representative flow cytometric analysis images (left) and the corresponding quantification (right) of MDSCs (CD11b+Gr-1+), gating on CD45+ cells. 
(D) Representative flow cytometric analysis images (left) and the corresponding quantification (right) of M2 macrophages (CD206+) in F4/80+ CD11b+ CD45+ cells.
(E) Confocal immunofluorescence images of B16F10 tumor with (right) or without (left) GEM@Gel treatment. Red and blue colors represent aPDL1 signals from Cy3- 
conjugated aPDL1 and 4′,6-diamidino-2-phenylindole (DAPI) staining of nuclei, respectively. Scale bar, 20 m. (F) PD-L1 expression of tumor cells and PD-1 expression of 
TILs after empty hydrogel or GEM@Gel treatment and the corresponding quantification of PD-L1 and PD-1 mean fluorescence intensity (MFI). a.u., arbitrary units; DC,
dendritic cell. (G) Systemic IL-6 and IFN- concentrations before and after GEM@Gel treatment. Data are means ± SEM. Statistical significance was calculated by one-way 
analysis of variance (ANOVA) with Tukey’s post hoc test. *P < 0.05; **P < 0.01; ***P < 0.005.
implantation (Fig. 2G and fig. S12). Among them, interleukin-6 
(IL-6) and interferon- (IFN-) were significantly (P < 0.05) up- 
regulated after GEM@Gel implantation (Fig. 2G), and IFN- is 
known to induce PD-L1 expression in tumor cells (43–45). These 
results substantiate that GEM@Gel can elicit an inflamed and im-
munogenic TME.
Scaffold-mediated combination therapy
To validate whether the proposed combination chemoimmuno-
therapy strategy can promote antitumor effects, we used the B16F10 
mouse melanoma tumor model. Tumor-bearing mice were implanted 
peritumorally with GEM@Gel (200 l; 10%, w/w) (GEM, 5 mg/kg), 
aPDL1@Gel (aPDL1, 50 g per mouse), or aPDL1-GEM@Gel 
(aPDL1, 50 g per mouse; GEM, 5 mg/kg). Tumor growth was 
monitored by the bioluminescence signals of B16F10 cells (Fig. 3A). 
The empty hydrogel and GEM@Gel showed similar effects and were 
not superior to untreated control. aPDL1@Gel-treated mice showed a 
delay of tumor growth. In contrast, mice receiving aPDL1-GEM@Gel 
showed noticeable tumor inhibition effects (Fig. 3, B and C). The 
tumor sizes in mice correlated with their survival (Fig. 3D). Fifty percent 
of mice survived at least 60 days after treatment with aPDL1- GEM@Gel. 
In contrast, none of the mice survived in any of the control groups 
after 2 months (Fig. 3D). We compared aPDL1-GEM@Gel with non-
encapsulated GEM and aPDL1. aPDL1-GEM@Gel treatment was 
superior in inhibiting tumor growth compared to nonencapsulated 
drugs delivered locally or systemically (fig. S13).
Furthermore, tumors were harvested and analyzed by immuno-
fluorescence and flow cytometry on day 10 after treatments. aPDL1- 
GEM@Gel–treated mice showed marked infiltration with CD8+ 
and CD4+ T cells compared to the untreated mice (Fig. 3E). Tumor 
weights were also significantly (P < 0.001) lower in the aPDL1- 
GEM@Gel–treated mice on day 10 (fig. S14), which paralleled an 
increase in absolute numbers of TILs (fig. S14). More strikingly, the 
absolute number of CD8+ T cells per gram of tumor increased 
by more than 20-fold in the aPDL1-GEM@Gel–treated mice com-
pared with the untreated control and 2.5-fold over that of the 
Fig. 3. Local gel scaffold for inhibition of B16F10 melanoma growth in vivo. (A) In vivo bioluminescence imaging of the B16F10 tumor in control and treated groups. 
Three representative mice of 7 to 10 mice per treatment group are shown. (B and C) Individual (B) and average (C) tumor growth kinetics in control and treated groups 
(treatment started at day 0). Inset: Representative mouse photographs 2 weeks after treatment. White arrows indicate the tumors. Growth curves represent means ± SEM; 
growth curves were stopped when the first animal of the corresponding group died. (D) Survival curves for the treated and control mice (n = 7 to 10). ***P < 0.001. 
(E) Immunofluorescence of tumors showing CD4+ and CD8+ T cell infiltration. Scale bar, 100 m. (F and G) Absolute numbers of the CD8+ (F) and CD4+ T cells (G) per gram 
of the tumor upon various treatments. (H and I) Ratios of the tumor-infiltrating CD8+ T cells (H) and CD4+ T cells (I) to Tregs in the tumors upon various treatments. Teff, 
effector T cell. Data are means ± SEM. Statistical significance was calculated by one-way ANOVA with Tukey’s post hoc test. *P < 0.05; **P < 0.01; ***P < 0.005.
aPDL1@Gel-treated mice (Fig. 3F and fig. S14). In addition, the in-
tratumoral ratios of effector T cells to Tregs were increased in mice 
after aPDL1- GEM@Gel therapy (Fig. 3, G to I, and fig. S14). Together, 
these observations suggest that aPDL1-GEM@Gel implantation 
triggers a robust T cell–mediated antitumor immune response.
To assess whether the local delivery of aPDL1-GEM@Gel also 
induces systemic immune responses, tumor cells were inoculated 
on the opposite site of the primary tumor in which the hydrogel was 
implanted (Fig. 4A). We observed that PD-L1 was up-regulated by 
tumor cells at both tumor sites compared to tumors in the untreated 
mice (Fig. 4, B and C). This could be explained by the systemic dis-
tribution of cytokines locally induced by aPDL1-GEM@Gel im-
plant (Fig. 2G). For example, blocking systemic IFN- by a neutral-
izing antibody decreased the PD-L1 up-regulation in the distant 
tumor (fig. S15). Furthermore, tumor bioluminescence (Fig. 4, 
D and E) and tumor weight (Fig. 4F) significantly (P = 0.0029) de-
creased in both hydrogel-implanted and untreated tumor sites 
(Fig. 4G), with corresponding increased infiltration of CD3+CD8+ 
T cells compared to the untreated control mice (Fig. 4, H and I). 
T cell memory response was also generated in mice treated with 
aPDL1-GEM@Gel, as they showed increased frequency of endoge-
nous CD44+CD122hi central memory T cells (46–50) in the spleen 
Fig. 4. Local gel scaffold for systemic anticancer immune response. (A) Mice were inoculated with tumor cells in the right and left flanks. Control mice were untreated, 
whereas treated mice were implanted with hydrogels only on the left flank. (B) PD-L1 expression of cancer cells collected from the tumor sites of the control and treated 
mice and (C) corresponding quantification of PD-L1 MFI (n = 3). (D) In vivo bioluminescence imaging of B16F10 tumors in response to local aPDL1-GEM@Gel treatment. 
(E) Left and right tumor growth curves and (F) tumor weight on day 10 in untreated and treated mice. (G) Representative photographs of mice on day 10 after treatment. 
White arrows indicate the tumors. (H) Percentages and representative dot plots of CD4+ and CD8+ T cells in tumors of control and treated mice and (I) absolute numbers 
of CD8+ cells per gram of tumor. Data are means ± SEM. Statistical significance was calculated by one-way ANOVA with Tukey’s post hoc test. *P < 0.05; ***P < 0.005.
as compared to the control groups (Fig. 5, A to C). When rechal-
lenged with tumor cells, mice that had no detectable tumors after 
treatment with aPDL1-GEM@Gel did not show significant re-
growth of tumor, as indicated by bioluminescence imaging of the 
lungs (Fig. 5D), photographs of the lungs (Fig. 5E), and hematoxylin 
and eosin (H&E) staining (Fig. 5F). Overall survival was also signifi-
cantly (P = 0.0039) better compared to the control group (Fig. 5G). 
These results indicate that systemic antitumor effects and memory 
T cell formation can be achieved by local treatment with aPDL1- 
GEM@Gel.
To further demonstrate that our proposed chemoimmunotherapy 
could be broadly applicable, we implemented the 4T1 tumor model 
of triple-negative breast cancer. 4T1 cells were reported to express 
low amounts of PD-L1 (38). In vitro experiments showed that GEM 
induced PD-L1 expression in 4T1 cancer cells (fig. S16). For in vivo 
study, 4T1 cells were inoculated subcutaneously into the right flank 
of female BALB/c mice. After 14 days, the mice bearing 4T1 tumors 
were treated with GEM@Gel (200 l; 10%, w/w) (GEM, 5 mg/kg), 
aPDL1@Gel (aPDL1, 50 g per mouse), or aPDL1-GEM@Gel (aPDL1, 
50 g per mouse; GEM, 5 mg/kg). Encouragingly, we found that 
aPDL1-GEM@Gel promoted anticancer effects in 4T1-bearing 
mice as indicated by the bioluminescence imaging (Fig. 6A). Tumor 
growth was suppressed in mice treated with aPDL1-GEM@Gel 
(Fig. 6B), which also prolonged survival (Fig. 6C).
Toxic effects always need serious concern when studying combi-
nation therapies. PVA with high molecular weight is considered to 
be highly biologically compatible and eliminated from the body via 
biliary excretion (51, 52). Body weights of mice were not significant-
ly affected after receiving hydrogels loaded with GEM and aPDL1 
(fig. S17A). In addition, histology analysis of organs obtained from 
mice 40 days after treatment indicated no appreciable abnormality 
or noticeable organ damage (fig. S17B).
Therapeutic scaffold for prevention of postsurgical  
tumor recurrence
To further investigate the potency of the in situ formed ROS-responsive 
scaffold, we performed experiments in a B16F10 incomplete tumor 
resection model (53, 54). ROS-responsive scaffolds containing GEM, 
aPDL1, or both were directly injected into the resection cavity. Sys-
temically or locally administered nonencapsulated drugs were also 
included as control groups. Mice receiving aPDL1-GEM@Gel were 
more protected from local tumor recurrence (with 30% tumor re-
currence rate) (Fig. 7, A to D), with significantly (P < 0.001) higher 
survival rate compared to other groups (Fig. 7E). The body weights 
Fig. 5. Local gel scaffold for T cell 
memory response. (A) Splenocytes 
isolated from tumor-bearing control 
and treated mice were analyzed for 
the presence of CD8+CD44+CD122+ 
and CD4+CD44+CD122+ central mem-
ory T cells (TCM). (B and C) Correspond-
ing quantification of CD4 (B) and CD8 
(C) TCM in splenocytes. (D) In vivo
bioluminescence imaging of mice
after rechallenging with intrave-
nous injection of B16F10 cancer cells. 
(E) Representative lung photographs 
(day 10) and (F) H&E staining of lungs
collected from control (naïve) and
treated (cured) mice after rechalleng-
ing. The blue arrowheads indicate
metastatic tumors in the lungs. Scale 
bar, 100 m. (G) Survival curves for
naïve and treated mice. Six mice for 
each group are shown. Data are means ±
SEM. Statistical significance was cal-
culated by one-way ANOVA with Tukey’s 
post hoc test. **P < 0.01.
of mice did not significantly vary during the treatment (fig. S18). In 
addition, similar results were obtained in the 4T1 tumor recurrence 
model [we used non–luciferase-expressing 4T1 tumor in this exper-
iment to avoid immune response against the luciferase reporter 
(55)] (Fig. 8). aPDL1-GEM@Gel treatment prevented cancer recur-
rence without obvious toxicity (Fig. 8). Collectively, these results 
suggest that ROS-responsive scaffolds serve as a therapeutic depot 
to enhance ICB after surgery to inhibit cancer recurrence.
DISCUSSION
We have demonstrated that an in situ formed hydrogel scaffold con-
sisting of a ROS-sensitive moiety can locally deliver GEM and 
aPDL1 with distinct kinetics in tumor-bearing mice to promote an 
immunogenic tumor phenotype and immune-mediated tumor re-
jection. Previous reports showed that PD-L1 expression in tumor 
cells was considerably increased after chemotherapy, resulting in 
PD-L1–mediated T cell exhaustion (56, 57). We therefore hypothe-
sized that greater anticancer efficacy could be achieved by local ad-
ministration of chemotherapeutics and ICB inhibitor with distinct 
kinetics. To achieve this cascade-like treatment at the tumor site, a 
ROS-responsive hydrogel scaffold was synthesized and loaded with 
GEM and aPDL1, taking into account that ROS are abundant in the 
TME. After in situ construction, the ROS-responsive hydrogel re-
leased both GEM and aPDL1 in a ROS-dependent manner. The 
smaller molecular weight of GEM compared to aPDL1 contributed 
to its faster release from the hydrogel.
GEM is a ribonucleotide reductase inhibitor that has a broad 
spectrum of antitumor activity (58). We observed up-regulation of 
PD-L1 and PD-1 expression in tumor 
cells and TILs, respectively, upon expo-
sure to the GEM@Gel. GEM@Gel also 
reduced tumor-infiltrating MDSCs, which 
contribute to dysfunction of effector 
T cells (37). Because GEM inhibits in-
tratumoral MDSCs (58), their depletion 
upon the implantation of GEM@Gel 
was not surprising. Following a similar 
pattern, GEM@Gel also induced an en-
hancement of T cell infiltration and a 
loss of TAMs expressing CD206. How-
ever, loss of TAMs and reduction of 
ROS were also observed in mice treated 
with the empty hydrogel. Because ROS 
is critical for macrophage differentia-
tion, ROS depletion caused by the hy-
drogel may contribute to recruiting 
T cells into the tumor site as well as 
blocking M2 macrophage differentia-
tion (59). Therefore, the ROS- responsive 
scaffold may not only act as a reser-
voir to control the release of therapeu-
tics but also serve as a scavenger of ROS 
within the TME to enhance treatment 
efficacy.
aPDL1-GEM@Gel induced an im-
munogenic tumor phenotype, and the 
activity of the aPDL1 promoted tumor 
regression in the B16F10 melanoma 
and 4T1 breast tumor mouse models—the latter of which has 
relatively low PD-L1 expression (38). Moreover, the local treatment 
generated a systemic anticancer immune response that inhibited 
distant tumor growth. Collectively, the proposed combined chemo-
immunotherapy strategy may offer opportunities for treating poorly 
immunogenic tumors and reducing systemic toxicities. Further-
more, the scaffold can also be applied to the surgical bed of resected 
tumors, which is also abundant in ROS (60), making this strategy 
clinically relevant for inhibiting cancer recurrence postoperatively. 
Our scaffold generated inside the resection cavity may contribute 
to scavenging ROS and thus also reduce the inflammation. Finally, 
although ICB is considered to be tolerated by patients, combination 
therapy may increase the risk of side effects. Here, we did not ob-
serve any obvious toxicity in mice treated with the drug-loaded 
scaffolds.
Regarding further translation for clinical applications, long-term 
toxicity of using the scaffold should be thoroughly evaluated. In ad-
dition, the dosages of combination drugs as well as treatment fre-
quencies could be further studied and optimized.
In summary, we have developed a combined chemoimmuno-
therapy strategy based on the controlled release of chemotherapeutic 
drug and ICB inhibitor from a TME-responsive hydrogel scaffold. 
GEM released by the hydrogel scaffold elicits immunogenic pheno-
types in tumors. Notably, the ROS-responsive gels can not only 
serve as a reservoir for tuning release of therapeutics but also function 
as a scavenger of ROS and thus further enhance the immunogenic 
phenotypes. This strategy holds promise for treating low-immunogenic 
tumors that are poorly responsive to ICB. Moreover, because 
the local implantation of the scaffold promotes systemic immune 
Fig. 6. Local gel scaffold for treatment of low-immunogenic 4T1 carcinoma tumor. (A) In vivo bioluminescence 
imaging of the 4T1 tumor growth in control and treated mice. (B) Tumor growth kinetics in control and treated mice. 
Growth curves represent means ± SEM; growth curves were stopped when the first animal of the corresponding 
group was euthanized. (C) Survival curves for control and treated mice (n = 5 to 10). Statistical significance was calculated 
by one-way ANOVA with Tukey’s post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001.
Fig. 7. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. (A) In vivo bioluminescence imaging of the B16F10 tumor growth in C57B6 mice after 
various treatments as indicated. (B to D) Individual (B) and average quantitative bioluminescence signals of tumors (C) and tumor growth kinetics (D) in control and 
treated groups. Black arrows indicate the day of the surgery (day 9). (E) Survival curves for different treatments (n = 7 to 10). Growth curves were stopped when the first 
animal of the corresponding group was euthanized. Data are means ± SEM. Statistical significance was calculated by one-way ANOVA with Tukey’s post hoc test. *P < 0.05; 
**P < 0.01; ***P < 0.001.
Fig. 8. Gel scaffold for 
inhibition of postsurgi-
cal recurrence of 4T1 tu-
mors. (A) Individual and 
(B) average tumor growth 
kinetics in control and treat-
ed groups receiving the in-
dicated treatments. Growth 
curves were stopped when 
the first animal of the cor-
responding group was eu-
thanized or dead. (C) Survival
curves for different treat-
ments (n = 5 to 9, as indi-
cated in the figure). (D) Mea-
surements of body weight 
of control and treated mice. 
Black arrows indicate the 
day of the surgery (day 14). 
Data are means ± SEM. Statistical significance was calculated by one-way ANOVA with Tukey’s post hoc test. *P < 0.05.
responses and T cell memory formation, this strategy may be 
useful to treat metastatic tumors and inhibit tumor recurrence.
MATERIALS AND METHODS
Study design
The objective of the study was to develop a strategy based on con-
trolled release of chemotherapeutic drug and ICB from a TME- 
responsive hydrogel scaffold for enhancing response and efficiency 
of ICB therapy. The in vivo antitumor efficacy was assessed in 
B16F10 and 4T1 tumors and incomplete tumor resection models. 
Mice from varying treatment groups were followed to create survival 
curves, imaged to assess tumor progression, and rechallenged with 
tumor to assess immune memory. Sample sizes were determined 
on the basis of our previous experimental experience. Animals 
were randomly assigned to groups based on tumor size and body 
weight. The investigators were not blinded to allocation during 
experiments and outcome assessment. Animals were euthanized 
when exhibiting signs of impaired health or when the volume of 
the tumor exceeded 1.5 cm3. All experiments were run at least in 
triplicate.
Materials
All chemicals were purchased from Sigma-Aldrich unless otherwise 
specified and were used as received. GEM hydrochloride (United 
States Pharmacopeia reference standard) was purchased from Sigma 
(catalog no. 1288463). aPDL1 used in vivo was purchased from 
BioLegend Inc. (catalog no. 124329, clone 10F.9G2).
Cell lines
The mouse melanoma cell line B16F10 and mouse mammary car-
cinoma cell line 4T1 were purchased from the American Type 
Culture Collection. B16F10-luc-GFP and 4T1-luc-GFP cells were 
gifts from L. Huang at the University of North Carolina at Chapel 
Hill (UNC-CH). B16F10 cells were maintained in Dulbecco’s 
modified Eagle’s medium (Gibco, Invitrogen) supplemented 
with 10% fetal bovine serum (Invitrogen), penicillin (100 U/ml; 
Invitrogen), and streptomycin (100 U/ml; Invitrogen). 4T1 cells 
were maintained in RPMI 1640 medium (Gibco, Invitrogen) 
supplemented with 10% fetal bovine serum (Invitrogen), penicillin 
(100 U/ml; Invitrogen), and streptomycin (100 U/ml; Invitrogen). 
Master and working cell banks were generated immediately 
upon receipt. The third and fourth passages were used for the 
experiments. Cells were tested every 3 months to exclude the pres-
ence of mycoplasma. Authentication of cells was not performed 
after receipt.
Mice
C57BL/6 and BALB/c mice were purchased from The Jackson 
Laboratory. Age-matched (6 to 10 weeks) female mice were 
used  throughout all experiments. We performed all mouse 
studies in accordance with the animal protocol approved by the 
Institutional Animal Care and Use Committee at UNC-CH 
and North Carolina State University (NCSU). Experimental group 
sizes were approved by the regulatory authorities for animal wel-
fare after being defined to balance statistical power, feasibili-
ty, and ethical aspects. All mice were kept in accordance with 
federal and state policies on animal research at UNC-CH and 
NCSU.
Antibodies
aPDL1 used in vivo was purchased from BioLegend Inc. (catalog 
no. 124329, clone 10F.9G2). Antibodies used for flow cytometry in-
cluded CD3 (catalog no. A18644, Thermo Fisher Scientific), CD4 
(catalog no. A18667, Thermo Fisher Scientific), CD8 (catalog no. 
A18609, Thermo Fisher Scientific), PD-1 (catalog no. 135227, Bio-
Legend), CD11c (catalog no. 117309, BioLegend), PD-L1 (catalog 
no. 124311, BioLegend), CD11b (catalog no. 101211, BioLegend), 
and intracellular FOXP3 (catalog no. 71-5775-40, eBioscience). 
The stained cells were analyzed on a CytoFLEX flow cytometer 
(Beckman Coulter). A minimum of 1000 events per plot were col-
lected and analyzed using FlowJo software (version 10). Second-
ary antibodies including goat anti-rat IgG (H+L) (catalog no. 
A18866, Thermo Fisher Scientific), rabbit anti-rat IgG (H+L) 
(catalog no. A18920, Thermo Fisher Scientific), and goat anti-rat 
IgG (minimal x-reactivity) (catalog no. 405408, BioLegend) were 
used for immunostaining.
Synthesis of TSPBA
N,N,N′,N′-tetramethyl-1,3-propanediamine (0.1 g, 0.75 mmol) and 
4-(bromomethyl)phenylboronic acid (0.5 g, 2.3 mmol) were dis-
solved in dimethylformamide (10 ml) and mixed together. After 
stirring at 60°C overnight, the mixture was poured into tetrahydro-
furan (THF) (100 ml), filtered, and washed with THF (3 × 20 ml). 
After drying under vacuum overnight, pure TSPBA (0.3 g, yield 
70%) was obtained. 1H nuclear magnetic resonance (300 MHz, 
d-DMSO, ): 8.132 (s, 4H), 7.85 (d, 4H), 7.49 (d, 4H), 4.58 (s, 4H),
3.26 (s, 4H), 2.97 (s, 12H), 2.38 (m, 2H) (fig. S2).
Formation of PVA-TSPBA hydrogels
PVA (72 kDa; 98% hydrolyzed; 5 g) and deionized water (100 ml) 
were mixed together and stirred at 90°C to acquire a clear solution. 
TSPBA [5 weight % (wt %) in H2O, 2 ml] and PVA (5 wt % in H2O, 
2 ml) were mixed together, and a hydrogel was formed instant-
ly. This hydrogel was used for in vitro experiments. For the fabri-
cation of GEM- and aPDL1-loaded gel, predetermined amount of 
GEM or aPDL1 was added to the PVA aqueous solution. For in vivo 
application, PVA and TSPBA aqueous solutions were loaded into 
dual syringes and injected directly toward tumors to form a gel 
in situ.
Characterization of aPDL1-GEM@Gel
Cryo-SEM imaging was obtained by JEOL 7600F with Gatan Alto. 
Fluorescence imaging was analyzed using a confocal microscope 
(Zeiss LSM 710). The dynamic rheological behavior of PVA before 
and after gelation at 25°C was measured using a TA Instruments AR 
2000 stress controlled rheometer with 25-mm aluminum cross-
hatched parallel plates.
GEM and aPDL1 release from PVA-TSPBA hydrogels
Release studies were performed at 37°C with constant agitation in 
PBS. H2O2 (Sigma) was added to samples to study the GEM and 
antibody release. The released GEM was analyzed by HPLC, and the 
antibody release was determined by the Rat IgG Total ELISA Kit 
(eBioscience).
In vivo tumor models
To test the anticancer effects in mouse models, mice were studied 
9 days after 1 × 106 of luciferase-tagged B16F10 or 14 days after 1 × 106 
of luciferase-tagged 4T1 tumor cells were transplanted into the 
right flank of mice. Mice were weighed and randomly divided into 
different groups (n = 7 to 10). The mice were peritumorally im-
planted with different formulations, including hydrogels, GEM@
Gel, aPDL1@Gel, and aPDL1-GEM@Gel (aPDL1, 50 g per mouse; 
GEM, 5 mg/kg; 200 l; 10%, w/w). The tumor burden was moni-
tored by the bioluminescence signal of cancer cells. Images were 
taken using an IVIS Lumina imaging system (Caliper). The tumors 
were also measured with a digital caliper. The tumor volume (mm3) 
was calculated as (long diameter × short diameter 2)/2.
To measure the effects on cancer recurrence, 9 days after 1 × 106 
of B16F10/luciferase-tagged B16F10 or 14 days after 1 × 106 of 4T1/
luciferase-tagged 4T1 tumor cells were transplanted into the right 
flank of mice, the tumors were resected, leaving about 1% residual 
tissue behind to mimic the residual microtumors in a surgical bed 
(53, 54). Briefly, animals were anesthetized with isoflurane (1 to 3% 
for maintenance; up to 5% for induction) anesthesia via chamber 
induction and maintained via nose cone. The amount of residual 
tumor tissue was determined by the bioluminescence signals of tu-
mor cells before and after resection. The tumor area was clipped 
and aseptically prepared. Sterile instruments were used to remove 
roughly 99% of the tumor. The amount of residual tumor tissue was 
determined by the integrated bioluminescence signal intensity of 
the tumor tissues before and after tumor resection. The wound was 
closed by Autoclip wound clip system. Mice were weighed and ran-
domly divided into different groups (n = 5 to 10). After surgery, 
different formulations were implanted into the surgical bed, includ-
ing hydrogels, GEM@Gel, aPDL1@Gel, and aPDL1-GEM@Gel. 
Free GEM + aPDL1 at the same dose were locally or systemically 
administered into mice after resection of primary tumors. The tu-
mor burden was monitored by the bioluminescence signal of cancer 
cells. The mice were clipped and shaved using a depilatory cream 
before imaging, if necessary. The tumors were also measured with a 
digital caliper. The tumor volume (mm3) was calculated as (long 
diameter × short diameter 2)/2. Animals were euthanized with car-
bon dioxide when exhibiting signs of impaired health or when the 
volume of the tumor exceeded 1.5 cm3.
In vivo bioluminescence and imaging
Bioluminescence images were collected with the IVIS Spectrum Imaging 
System (PerkinElmer Ltd.). Living Image software (PerkinElmer Ltd.) 
was used to acquire the data 10 min after intraperitoneal injection 
of d-luciferin (Thermo Scientific Pierce) in Dulbecco’s PBS (15 mg/ml) 
into the animals (body weight, 10 l/g). Exposure time for biolumi-
nescence imaging was 5 min. Regions of interest were quantified as 
average radiance (photons s−1 cm−2 sr−1, represented by color bars) 
(IVIS Living Image 4.2).
Cytokine detection
The plasma concentrations of IL-2, IL-6, IL-10, IFN-, and TNF- 
(tumor necrosis factor–) were measured by LEGENDplex Mouse 
Th1 Panel multiple assay (catalog no. 740025, BioLegend) accord-
ing to the manufacturer’s instructions. The plasma was collected 
from mice before and 2 days after GEM@Gel implantation.
Confocal microscopy
Harvested tumors were dissected and snap-frozen in optimal cut-
ting temperature compound (Thermo Fisher Scientific). Micrometer 
sections were cut using a cryotome and mounted on slides. Sections 
were fixed in ice-cold acetone for 10 min before rehydration with 
PBS. After blocking with bovine serum albumin (3%), sections were 
stained with primary antibodies overnight at 4°C. After the addition 
of fluorescence-labeled secondary antibodies, the slides were an-
alyzed using a confocal microscope (Zeiss LSM 710).
Statistical analysis
All results are expressed as means ± SD or means ± SEM, as indicated. 
Biological replicates were used in all experiments unless stated oth-
erwise. ANOVA was performed when more than two groups were 
compared, and when the result was significant (P < 0.05), multiple 
comparisons were performed using Tukey’s post hoc test. Statistical 
differences in survival were determined with the log-rank test. All 
statistical analyses were performed with GraphPad Prism (5.0). *P < 
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Fig. S2. Synthesis route and characterization of TSPBA.
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